Beth Clark, 48, was diagnosed three months ago with invasive ductal carcinoma, the most common type of breast cancer. She had a full double bilateral mastectomy, but less than 24 hours before her reconstruction surgery, her insurance company Anthem Blue Cross and Blue Shield denied coverage for the procedure. According to her denial letter, the surgery involving a surgical mesh called GalaFlex is still considered investigational and there is no or not enough proof it improves health. GalaFlex is a synthetic surgical mesh that is not FDA-approved for breast reconstruction and is still considered an off-label, investigational, and experimental treatment. In a 2023 letter to health care providers, the FDA reiterated that its efficacy and safety for breast cancer patients have not been determined.

Dr. Alicia Billington, Clark's plastic surgeon, uses GalaFlex mesh on most of her breast reconstruction patients and says the product is giving her patients the least amount of complications.

Billington recently shared Clark's denial on social media and took part in a viral dance with friends to call for policy changes. Last year, Cigna became the first and only major insurer to start approving GalaFlex for breast reconstruction. Despite her insurer's denial, Clark got her reconstruction surgery with the GalaFlex mesh a little more than a week ago thanks to Billington finding a mechanism to make that happen. Clark and Billington are still fighting the denial.